Benzinga | Jan 27, 2021 07:23AM EST

AbCellera Highlights Its Discovered Antibody, Bamlanivimab, To Be Developed With VIR-7831 For The Treatment Of COVID-19

AbCellera (NASDAQ:ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19. Bamlanivimab is currently a component in all Lilly's antibody-based COVID-19 therapies, which include bamlanivimab alone, and bamlanivimab and etesevimab together. Lilly will expand the ongoing BLAZE-4 trials to evaluate bamlanivimab together with VIR-7831. Details about Lilly's trial are available here.